Abstract Library

#3089 Mixed Large and Small Cell Neuroendocrine Carcinoma of the Endometrium: A Case Report and Literature Review

Introduction: Neuroendocrine carcinoma (NEC) is an extremely rare subtype of endometrial cancer which is usually seen among perimenopausal or postmenopausal women. It runs an aggressive course and posts a clinical challenge due to limited treatment options available.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cruz M

Authors: Cruz M, Uyboco J,

Keywords: neuroendocrine carcinoma, endometrium,

#3084 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): A Case Report and Review of Literature

Introduction: Majority of euroendocrine tumorsare found in the gastrointestinal tract and bronchopulmonary. Multifocal disease is common among patients with low-grade NET. One example of this is diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. DIPNECH is an extremely rare but indolent disease with predilection for nonsmoking, middle-aged women.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cruz M

Authors: Cruz M,

Keywords: DIPNECH, Neuroendocrine tumor, carcinoid,

#2757 Effectiveness of Lanreotide 120 mg (LAN) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (panNET) in Routine Clinical Practice

Introduction: PanNETs are the second most common type of tumour of the pancreas. Most patients have metastatic disease at diagnosis with median survival ranges from 2 to 5 years. Somatostatin analogs (SSAs) control symptoms and reduce tumour growth in panNET. In the panNET subgroup of the CLARINET study, lanreotide autogel 120 mg reduced the relative risk of progression or death by more than 40% compared with placebo at week 96.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Teulé A, Alonso T, González E, De La Cruz G, Houchard A,

Keywords: NET, lanreotide, pancreas, study,

#2058 On-going Evaluation of the Use of Resources and the Costs (UR/C) Associated with Controlled or Uncontrolled Carcinoid Syndrome (CS) in Patients (pts) with Neuroendocrine Tumours (NETs): RECOSY Study Design

Introduction: NET pts have high rates of mortality and morbidity, as wells as decreased health-related quality of life (HRQoL) due to CS. Though there is little research on the economic impact of CS, recent studies show that some symptoms, i.e. diarrhoea, are associated with higher healthcare expenditure and use of resources.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Custodio A, Carmona-Bayonas A, Villabona C, Perez M, de La Cruz G,

Keywords: neuroendocrine tumors, carcinoid syndrome, use of resources, costs,

#1851 Ecological Study to Assess the Management of Gastroenteropancreatic Neuroendocrine Tumors in Spain

Introduction: Neuroendocrine tumors (NET) have widely varying characteristics, localizations, and treatments. Consequently, a multidisciplinary approach to diagnosis and treatment is necessary. Given the heterogeneous management of this disease, we conducted an ecological survey to assess usual clinical practice in Spain.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Guardeño R, García P, Ginés R, De la Cruz G,

Keywords: gastrointestinal, neuroendocrine, pancreatic tumors, survey, Spain,